Iterum Therapeutics PLC
NASDAQ:ITRM
Intrinsic Value
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ITRM.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Iterum Therapeutics PLC's business.
What risks and challenges
does Iterum Therapeutics PLC face in the near future?
Summarize the latest earnings report
of Iterum Therapeutics PLC.
Provide P/E
for Iterum Therapeutics PLC and its competitors.
Balance Sheet Decomposition
Iterum Therapeutics PLC
Current Assets | 38.5m |
Cash & Short-Term Investments | 35.9m |
Other Current Assets | 2.6m |
Non-Current Assets | 1.2m |
PP&E | 700k |
Intangibles | 400k |
Other Non-Current Assets | 100k |
Current Liabilities | 16.4m |
Accounts Payable | 5.5m |
Accrued Liabilities | 9.4m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 19.9m |
Long-Term Debt | 19.6m |
Other Non-Current Liabilities | 300k |
Earnings Waterfall
Iterum Therapeutics PLC
Revenue
|
0
USD
|
Operating Expenses
|
-44m
USD
|
Operating Income
|
-44m
USD
|
Other Expenses
|
12.9m
USD
|
Net Income
|
-31.1m
USD
|
Free Cash Flow Analysis
Iterum Therapeutics PLC
What is Free Cash Flow?
ITRM Profitability Score
Profitability Due Diligence
Iterum Therapeutics PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Iterum Therapeutics PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ITRM Solvency Score
Solvency Due Diligence
Iterum Therapeutics PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Iterum Therapeutics PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ITRM Price Targets Summary
Iterum Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for ITRM is 6.63 USD with a low forecast of 6.06 USD and a high forecast of 7.35 USD.
Ownership
ITRM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ITRM Price
Iterum Therapeutics PLC
Average Annual Return | -66.6% |
Standard Deviation of Annual Returns | 17.93% |
Max Drawdown | -100% |
Market Capitalization | 20.7m USD |
Shares Outstanding | 13 435 400 |
Percentage of Shares Shorted | 7.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.